Dr. Yeh is an experienced physician scientist and drug developer who has been responsible for the successful clinical development and registration of multiple transformative medicines, including anti-COVID monoclonal antibody sotrovimab. She currently oversees the clinical development of the Respiratory pipeline at Vir Biotechnology. Prior to that, she was at Principia Biopharma leading the clinical development of BTK inhibitors in multiple immune-mediated diseases and spent 7 years at Merck where she made significant contributions to the development of HCV therapies, as well as letermovir for prevention of cytomegalovirus in immunocompromised hosts. After receiving her undergraduate degree in Biology from Stanford University, Dr. Yeh earned her M.D. from University of Washington and completed her Internal Medicine training at Brigham and Women’s Hospital and her Infectious Disease fellowship at Massachusetts General Hospital in Boston. Prior to joining industry, Wendy held the position of Assistant Professor in Medicine at Harvard Medical School.
The COVID-19 pandemic is driving the unprecedented transformation of the global medical research ecosystem through the search for effective new therapeutics that can help ease symptoms and prevent death among COVID-19 patients.